Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.
Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG.
Claveria-Cabello A, et al. Among authors: avila ma.
Cancers (Basel). 2020 Dec 13;12(12):3748. doi: 10.3390/cancers12123748.
Cancers (Basel). 2020.
PMID: 33322158
Free PMC article.